8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonic acid | 1372761-09-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonic acid
• 英文别名: 8-Methoxy-3-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7-sulfonic acid；8-methoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonic acid
• CAS: 1372761-09-5
• 化学式: C₁₂H₁₇NO₄S
• 分子量: 271.337
• InChiKey: ZVAIGVNIRULSDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonic acid 在 氯化亚砜 作用下， 反应 0.5h， 生成 8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride
  参考文献：
  名称：

  [EN] 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OR TOSYLATE AS ANTIPSYCHOTICS
  [FR] 7-[4-(4-CHLOROBENZYLOXY) BENZENESULFONYL]-8-METHOXY-3-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINIUM MALEATE OU TOSYLATE EN TANT QU'AGENTS ANTIPSYCHOTIQUES

  摘要：

  本发明涉及7-[4-(4-氯苄氧基)苯基磺酰基]-8-甲氧基-3-甲基-2,3,4,5-四氢-1H-3-苯并哌啶的新型盐及其药学可接受的溶剂结晶体，药物配方、其制备方法以及在医学上的应用。这些化合物在治疗中具有用途，特别是作为抗精神病药物。

  公开号：

  WO2005051916A1
• 作为产物：
  描述：

  7-甲氧基-3-甲基-2,3,4,5-四氢-1H-苯并[d]氮杂卓 在 氯磺酸 作用下， 以 三氟乙酸 为溶剂， 反应 0.5h， 生成 8-methoxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonic acid
  参考文献：
  名称：

  [EN] 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS
  [FR] DERIVES DE 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE UTILISES EN TANT QU'AGENTS ANTIPSYCHOTIQUES

  摘要：

  这项发明提供了一种或多种从式(I)化合物及其药学上可接受的盐和溶剂中选择的化学实体。式(I)化合物和其药学上可接受的盐或溶剂在治疗中有用，特别是作为抗精神病药物。

  公开号：

  WO2005051399A1

文献信息

• [EN] 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DERIVES DE 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE EN TANT QU'AGENTS ANTIPSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2005051397A1

  公开（公告）日：2005-06-09

  The invention provides one or more chemical entities selected from a compound of formula (I): (I) wherein R1 represents C1-6alkyl, trifluoromethoxy or halo; R2 represents hydrogen, C1-6alkyl or halo; or when R1 and R2 are positioned at the 3- and 4-positions, R1 and R2 together with the carbon atoms to which they are attached may form a 1,4-dioxane ring; and a pharmaceutically acceptable salt and solvate thereof. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are useful in therapy, in particular as antipsychotic agents.

  该发明提供了一种或多种从式(I)的化合物中选择的化学实体：(I)其中R1代表C1-6烷基，三氟甲氧基或卤素；R2代表氢，C1-6烷基或卤素；或者当R1和R2位于3-和4-位置时，R1和R2与它们连接的碳原子一起可以形成1,4-二氧杂环己烷环；以及其药学上可接受的盐和溶剂化物。式(I)的化合物和其药学上可接受的盐和溶剂化物在治疗中特别作为抗精神病药剂是有用的。
• [EN] 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DERIVES DE 7-HETEROARYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE EN TANT QU'AGENTS ANTIPSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2005025576A1

  公开（公告）日：2005-03-24

  The invention provides compounds of formula (I): wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pOC3-6cycloalkyl, -COC1-6alkyl, -SO2 C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO2C1-6alkyl, -CO2NR3R4, -SO2NR3R4, -(CH2)pNR3R4, -(CH2)pNR3COR4, optionally substituted aryl ring, optionally substituted heteroaryl ring, a fused bicyclic heteroaromatic ring system or optionally substituted heterocyclyl ring; Ar1 represents optionally substituted heteroaryl ring; Ar2 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; Z represents -(CH2)qX- wherein the -(CH2)q- group is attached to Ar2, or -X(CH2)q- wherein X is attached to Ar2, and wherein any of the -CH2- groups may be optionally substituted by one or more C1-6alkyl groups; X represents oxygen, -CH(OR5)-, -NR5- or -CH2- wherein the -CH2- group may be optionally substituted by one or more C1-6alkyl groups; R3 and R4 each independently represent hydrogen, C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R5 represents hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that when Ar1 is a pyridyl group, and Z is -CH2X- where X is attached to the Ar1 group, X is selected from -CH(OR5)-, -NR5- and -CH2- wherein the -CH2- group may be optionally substituted by one or more C1-6alkyl groups. The compounds of formula (I) are useful in therapy, in particular as antipsychotic agents.

  该发明提供了以下式（I）的化合物：其中A和B分别代表基团-(CH2)m-和-(CH2)n-；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、-(CH2)pC3-6环烷基、-(CH2)pOC3-6环烷基、-COC1-6烷基、-SO2 C1-6烷基、-SOC1-6烷基、-S-C1-6烷基、-CO2C1-6烷基、-CO2NR3R4、-SO2NR3R4、-(CH2)pNR3R4、-(CH2)pNR3COR4、可选择地取代的芳基环、可选择地取代的杂芳基环、融合的双环杂芳基环系统或可选择地取代的杂环烷基环；Ar1代表可选择地取代的杂芳基环；Ar2代表可选择地取代的芳基环或可选择地取代的杂芳基环；Z代表-(CH2)qX-其中-(CH2)q-基团连接到Ar2，或-X(CH2)q-其中X连接到Ar2，并且任何一个-CH2-基团可以可选择地由一个或多个C1-6烷基基团取代；X代表氧、-CH(OR5)-、-NR5-或-CH2-其中-CH2-基团可以可选择地由一个或多个C1-6烷基基团取代；R3和R4各自独立地代表氢、C1-6烷基或者与它们连接的氮或其他原子形成氮杂环烷基环或氧代取代的氮杂环烷基环；R5代表氢或C1-6烷基；m和n独立地代表选自1和2的整数；p独立地代表选自0、1、2和3的整数；q独立地代表选自0、1、2和3的整数；或其药学上可接受的盐或溶剂，但当Ar1是吡啶基团，且Z为-CH2X-其中X连接到Ar1基团时，X选自-CH(OR5)-、-NR5-和-CH2-其中-CH2-基团可以可选择地由一个或多个C1-6烷基基团取代。该式（I）的化合物在治疗中特别作为抗精神病药物具有用途。
• [EN] PHENYLSULFONYL COMPOUNDS AS ANTIPSYCHOTIC AGENTS<br/>[FR] COMPOSES DE PHENYLSULFONYLE EN TANT QU'AGENTS ANTIPSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2005014578A1

  公开（公告）日：2005-02-17

  The invention provides compounds of formula (I): wherein A and B represent the groups -(CH 2) m- and -(CH 2) n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, -(CH 2)pC3-6cycloalkyl, -(CH2)pOC3-6cycloalkyl, -COC1-6alkyl, -SO2C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO2C1-6alkyl, -CO 2NR5R6, -SO2NR5R6, -(CH2)pNR5R6, -(CH2)pNR5COR6, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R3 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; R4 represents hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, trifluoromethyl, trifluoromethoxy, halogen, -OSO2CF3, -(CH2)pC3-6cycloalkyl, -(CH2) qOC1-6alkyl or -(CH2)pOC3-6cycloalkyl; X represents -CH- or N; Z represents a bond, -O-, -(CH2)r-, -CH2O-, -OCH2- or CPO; R5 and R6 each independently represent hydrogen, C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R7 and R8 represent hydrogen or C1-6alkyl, or R7 and R8 together represent -(CH2)s-; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q represents an integer selected from 1, 2 and 3; r represents an integer selected from 1, 2 and 3; s represents an integer selected from 2, 3 and 4; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that when X is N, Z is a bond, -(CH2)r- or CPO. The compounds of formula (I) are useful in therapy, in particular as antipsychotic agents.

  该发明提供了以下结构的化合物（I）：其中A和B分别代表基团-(CH 2) m-和-(CH 2) n-；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C 1-6 烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、-(CH 2)pC3-6环烷基、-(CH2)pOC3-6环烷基、-COC1-6烷基、-SO2C1-6烷基、-SOC1-6烷基、-S-C1-6烷基、-CO2C1-6烷基、-CO 2NR5R6、-SO2NR5R6、-(CH2)pNR5R6、-(CH2)pNR5COR6、可选择地取代的芳香环、可选择地取代的杂环芳香环或可选择地取代的杂环烷基环；R3代表可选择地取代的芳香环或可选择地取代的杂环芳香环；R4代表氢、羟基、C1-6烷基、C1-6烷氧基、三氟甲基、三氟甲氧基、卤素、-OSO2CF3、-(CH2)pC3-6环烷基、-(CH2) qOC1-6烷基或-(CH2)pOC3-6环烷基；X代表-CH-或N；Z代表键、-O-、-(CH2)r-、-CH2O-、-OCH2-或CPO；R5和R6各自独立地代表氢、C1-6烷基或与它们连接的氮或其他原子一起形成一个氮杂环烷基环或氧代取代的氮杂环烷基环；R7和R8代表氢或C1-6烷基，或R7和R8一起代表-(CH2)s-；m和n各自独立地代表从1和2中选择的整数；p独立地代表从0、1、2和3中选择的整数；q代表从1、2和3中选择的整数；r代表从1、2和3中选择的整数；s代表从2、3和4中选择的整数；或其药学上可接受的盐或溶剂，但当X为N时，Z为键、-(CH2)r-或CPO。公式（I）的化合物在治疗中很有用，特别是作为抗精神病药物。
• Compounds
  申请人：Forbes Thomson Ian

  公开号：US20050261279A1

  公开（公告）日：2005-11-24

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 ) p NR 5 R 6 , —(CF) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; Z represents —(CH 2 ) r X— wherein the —(CH 2 ) r — group is attached to R 3 , or —X(CH 2 ) r — wherein X is attached to R 3 , and wherein any of the —CH 2 — groups may be optionally substituted by one or more C 1-6 alkyl groups; X represents oxygen, —NR 7 or —CH 2 — wherein the —CH 2 — group may be optionally substituted by one or more C 1-6 alkyl groups; R 7 represents hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; r independently represents an integer selected from 0, 1, and 2; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.

  本发明提供了式（I）的化合物： 其中，A和B分别代表基团—（CH2）m—和—（CH2）n—；R1代表氢或C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR5R6、—SO2NR5R6、—（CH2）pNR5R6、—（CF）pNR5COR6、可选地取代的芳环、可选地取代的杂芳环或可选地取代的杂环基；R3代表可选地取代的芳环或可选地取代的杂芳环；R4代表氢、羟基、C1-6烷基、C1-6烷氧基、三氟甲基、三氟甲氧基、卤素、—OSO2CF3、—（CH2）pC3-6环烷基、—（CH2）qOC1-6烷基或—（CH2）pOC3-6环烷基；R5和R6各自独立地代表氢、C1-6烷基或与它们所连接的氮或其他原子一起形成氮杂环烷基或氧代取代的氮杂环烷基；Z代表—（CH2）rX—，其中—（CH2）r—基团连接到R3，或—X（CH2）r—，其中X连接到R3，其中任何一个—CH2—基团可以可选地被一个或多个C1-6烷基基团取代；X代表氧、—NR7或—CH2—，其中—CH2—基团可以可选地被一个或多个C1-6烷基基团取代；R7代表氢或C1-6烷基；m和n独立地代表选自1和2的整数；p独立地代表选自0、1、2和3的整数；q独立地代表选自1、2和3的整数；r独立地代表选自0、1和2的整数；或其药学上可接受的盐或溶剂。这些化合物在治疗中有用，特别是作为抗精神病药物。
• 7-Heteroarylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
  申请人：Cooper Gwyn David

  公开号：US20070093473A1

  公开（公告）日：2007-04-26

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 3 R 4 , —SO 2 NR 3 R 4 , —(CH 2 ) p NR 3 R 4 , —(CH 2 ) p NR 3 COR 4 , optionally substituted aryl ring, optionally substituted heteroaryl ring, a fused bicyclic heteroaromatic ring system or optionally substituted heterocyclyl ring; Ar 1 represents optionally substituted heteroaryl ring; Ar 2 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; Z represents —(CH 2 ) q X— wherein the —(CH 2 ) q — group is attached to Ar 2 , or —X(CH 2 ) q — wherein X is attached to Ar 2 , and wherein any of the —CH 2 — groups may be optionally substituted by one or more C 1-6 alkyl groups; X represents oxygen, —CH(OR 5 )—, —NR 5 — or —CH 2 — wherein the —CH 2 — group may be optionally substituted by one or more C 1-6 alkyl groups; R 3 and R 4 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R 5 represents hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that when Ar 1 is a pyridyl group, and Z is —CH 2 X— where X is attached to the Ar 1 group, X is selected from —CH(OR 5 )—, —NR 5 — and —CH 2 — wherein the —CH 2 — group may be optionally substituted by one or more C 1-6 alkyl groups. The compounds of formula (I) are useful in therapy, in particular as antipsychotic agents.

  本发明提供式（I）的化合物： 其中A和B分别代表基团—（CH2）m—和—（CH2）n—； R1代表氢或C1-6烷基； R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR3R4、—SO2NR3R4、—（CH2）pNR3R4、—（CH2）pNR3COR4、可选地取代的芳环、可选地取代的杂环、融合的双环杂芳基环系统或可选地取代的杂环基； Ar1代表可选地取代的杂环基； Ar2代表可选地取代的芳环或可选地取代的杂环基； Z代表—（CH2）qX—，其中—（CH2）q—基团连接到Ar2，或—X（CH2）q—，其中X连接到Ar2，其中任何一个—CH2—基团可选择地被一个或多个C1-6烷基基团取代； X代表氧、—CH（OR5）—、—NR5—或—CH2—，其中—CH2—基团可以选择地被一个或多个C1-6烷基基团取代； R3和R4各自独立地代表氢、C1-6烷基或与它们连接的氮或其他原子形成一个氮杂环烷基环或一个氧代取代的氮杂环烷基环； R5代表氢或C1-6烷基； m和n独立地代表选自1和2的整数； p独立地代表选自0、1、2和3的整数； q独立地代表选自0、1、2和3的整数； 或其药学上可接受的盐或溶剂，但当Ar1是吡啶基团，且Z为—CH2X—，其中X连接到Ar1基团时，X选自—CH（OR5）—、—NR5—和—CH2—，其中—CH2—基团可以选择地被一个或多个C1-6烷基基团取代。 式（I）的化合物在治疗中有用，特别是作为抗精神病药物。